MAPT and Alzheimer disease: Clinical data have suggested links between Type II diabetes (T2D) and AD, which some researchers have proposed to call a form of “Type III diabetes.” Animal models have shown that T2D promotes the formation of amyloid-β plaques, tau phosphorylation and neurofibrillary lesions, however in humans this evidence is scarce or ambigous.